View Older Stories View More Recent Stories

May 5, 2026 04:20AM Axsome Therapeutics (AXSM) PT Raised to $300 at B.Riley
May 4, 2026 04:17PM Axsome Therapeutics (AXSM) PT Raised to $246 at Baird
May 4, 2026 04:07PM Axsome Therapeutics (AXSM) PT Raised to $302 at RBC Capital
May 4, 2026 03:19PM Axsome Therapeutics (AXSM) PT Raised to $280 at Oppenheimer
May 4, 2026 01:15PM Axsome Therapeutics (AXSM) PT Raised to $260 at Guggenheim
May 4, 2026 12:23PM Axsome Therapeutics (AXSM) PT Raised to $258 at Piper Sandler
May 4, 2026 12:06PM Axsome Therapeutics (AXSM) PT Raised to $275 at TD Cowen
May 4, 2026 07:33AM Axsome Therapeutics (AXSM) PT Raised to $270 at H.C. Wainwright
May 4, 2026 07:01AM Axsome Therapeutics (AXSM) Misses Q1 EPS by 43c
May 1, 2026 11:25AM Axsome Therapeutics (AXSM) PT Raised to $255 at TD Cowen
Apr 30, 2026 05:15PM Axsome Therapeutics (AXSM) PT Raised to $250 at Oppenheimer
Apr 30, 2026 03:23PM Axsome Therapeutics (AXSM) PT Raised to $217 at Morgan Stanley
Apr 30, 2026 02:05PM Axsome Therapeutics (AXSM) Halted, News Pending
Apr 28, 2026 09:13AM Axsome Therapeutics (AXSM) PT Lowered to $228 at Mizuho
Apr 10, 2026 09:31AM Axsome Therapeutics (AXSM) PT Raised to $259 at UBS
Apr 2, 2026 08:28AM Piper Sandler on Axsome Therapeutics (AXSM): 'A High-Risk, High-Reward Opportunity'
Apr 1, 2026 05:41PM Oppenheimer on Axsome Therapeutics (AXSM): balipodect acquisition bolsters late-stage pipeline
Apr 1, 2026 12:10PM Jefferies on Axsome Therapeutics (AXSM): balipodect development rights acquisition 'adds depth to CNS pipeline'
Apr 1, 2026 07:15AM William Blair Shuffles Analyst Conviction List for April 2026
Mar 27, 2026 08:47AM Mizuho stays Outperform rated on Axsome Therapeutics (AXSM) amid scripts decline
Mar 25, 2026 06:07AM Axsome Therapeutics (AXSM) PT Raised to $245 at Guggenheim
Mar 20, 2026 11:06AM Mizuho stays Outperform on Axsome Therapeutics (AXSM) as Auvelity Rx growth accelerates
Mar 13, 2026 06:02AM RBC Capital Defending on Axsome Therapeutics (AXSM)
Feb 24, 2026 10:32AM Axsome Therapeutics (AXSM) PT Raised to $251 at UBS
Feb 24, 2026 09:04AM Wolfe Research Starts Axsome Therapeutics (AXSM) at Outperform
Feb 24, 2026 08:51AM Axsome Therapeutics (AXSM) PT Raised to $222 at RBC Capital
Feb 24, 2026 05:40AM Axsome Therapeutics (AXSM) PT Raised to $220 at Guggenheim
Feb 23, 2026 12:32PM Truist Securities Reiterates Buy Rating on Axsome Therapeutics (AXSM)
Feb 23, 2026 12:17PM Axsome Therapeutics (AXSM) PT Raised to $215 at TD Cowen
Feb 23, 2026 08:04AM Axsome Therapeutics (AXSM) Tops Q4 EPS by 17c
Feb 2, 2026 09:00AM RBC Capital on Axsome Therapeutics (AXSM): 'Still See Upside On ADA Approval And Launch'
Jan 20, 2026 06:39AM Axsome Therapeutics (AXSM) PT Raised to $260 at H.C. Wainwright
Jan 16, 2026 08:30AM Piper Sandler on Axsome Therapeutics (AXSM): 'Raising Stock PT And Remaining Bullish'
Jan 14, 2026 06:56AM Axsome Therapeutics (AXSM) Reiterated at Overweight by Cantor Fitzgerald
Jan 13, 2026 04:52AM Axsome Therapeutics (AXSM) PT Raised to $209 at Baird
Jan 12, 2026 07:08AM Axsome Therapeutics reports preliminary 2025 revenue of $638.5 million
Jan 8, 2026 03:37AM Morgan Stanley Downgrades Axsome Therapeutics (AXSM) to Equalweight
Jan 5, 2026 07:08AM Needham Names MindMed (MNMD) New Top Pick for 2026, Adds to Conviction List
Jan 5, 2026 06:40AM Axsome Therapeutics (AXSM) PT Raised to $200 at H.C. Wainwright
Jan 2, 2026 09:37AM Axsome Therapeutics (AXSM) PT Raised to $230 at B.Riley
Jan 2, 2026 08:53AM Truist Reiterates Buy Rating on Axsome Therapeutics (AXSM)
Jan 2, 2026 06:23AM Guggenheim Reiterates Buy Rating on Axsome Therapeutics (AXSM)
Dec 31, 2025 01:54PM Baird on Axsome Therapeutics (AXSM): 'Incrementally positive on regulatory updates'
Dec 31, 2025 01:20PM Leerink on Axsome Therapeutics (AXSM): 'This is very positive news'
Dec 31, 2025 01:19PM Axsome Therapeutics (AXSM) PT Raised to $217 at Mizuho
Dec 31, 2025 12:42PM Axsome Therapeutics (AXSM) PT Raised to $220 at Oppenheimer
Dec 31, 2025 12:19PM Morgan Stanley on Axsome Therapeutics (AXSM)
Dec 31, 2025 08:27AM Axsome Therapeutics (AXSM) PT Raised to $169 at Needham
Dec 31, 2025 08:25AM Truist on Axsome Therapeutics (AXSM): 'We fully expect ADA to be a significantly larger opportunity for AXS-05'
Dec 31, 2025 08:24AM TD Cowen on Axsome Therapeutics (AXSM): 'the sNDA acceptance should be well received by investors'
View More Recent Stories View Older Stories